Answers are grounded in this paper and cite their sources.
Explores inducing dormancy in cancer cells using hibernation-based agents, suggesting a novel treatment approach.
Relapse in cancer is often driven by disseminated tumor cells (DTCs) that enter a dormant, non-proliferative state and later reactivate. Conventional pharmacology primarily focuses on eradicating dividing cells but lacks tools to induce and maintain a benign dormant state. Mammalian hibernation offers a natural, reversible model of systemic cellular quiescence mediated by dynamic epigenetic reprogramming. Here, we propose that studying and pharmacologically mimicking the epigenetic landscape of hibernators may provide a novel class of agents, "dormostatics", to lock DTCs into safe dormancy. We discuss key epigenetic features of torpor (DNA methylation shifts, histone modifications, sirtuin and SUMO pathways), their analogues in cancer cell biology, and articulate a translational roadmap toward epigenetic dormancy pharmacology. Finally, we highlight major outstanding questions and key clinical considerations.
No takes yet. Share an insight, caveat, or question.
Jafari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: